Wikisage, the free encyclopedia of the second generation, is digital heritage
Brivaracetam: Difference between revisions
Jump to navigation
Jump to search
m (and Neurol 2016 Nov;9(6):474-482. Epub 2016 Sep 1.) |
No edit summary |
||
| Line 1: | Line 1: | ||
4n propyl analog of [[levetiracetam]], this and levetiracetam may have potential in the management of progressive myoclonic [[epilepsy|epilepsies]] | 4n propyl analog of [[levetiracetam]], this and levetiracetam may have potential in the management of progressive myoclonic [[epilepsy|epilepsies]] | ||
| Line 11: | Line 11: | ||
===ATC=== | ===ATC=== | ||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
|colspan=2| <center> | |colspan=2| <center><gallery>File:Brivaracetam3d.png|(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide</gallery> | ||
: [[wikipedia:brivaracetam|brivaracetam]] | : [[wikipedia:brivaracetam|brivaracetam]] | ||
<ref>http://www.whocc.no/atc_ddd_index/?code=N03AX23</ref></center> | <ref>http://www.whocc.no/atc_ddd_index/?code=N03AX23</ref></center> | ||
|} | |} | ||
{{Wikidata|Q408099}} | |||
Latest revision as of 01:58, 10 July 2019
4n propyl analog of levetiracetam, this and levetiracetam may have potential in the management of progressive myoclonic epilepsies
[1][2]Like levetiracetam (LEV), it is a ligand of the synaptic vesicle protein SV2A[3]
Links
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm
ATC
|
![(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide](/wiki/File:Brivaracetam3d.png)
- ↑ Profile of brivaracetam and its potential in the treatment of epilepsy
- ↑ Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset
- ↑ Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AX23